FUJIFILM Diosynth Biotechnologies的动态

I've been lucky to have had a front row seat to see all the incredible progress in advanced therapeutics over the past decade. Looking ahead, there's even more exciting things to come. Oligos, for example, are proving to be a promising tool in the development of a wide range of new treatments and innovative applications in genomic medicine. But time and cost challenges are common when manufacturing oligonucleotides. It's crucial to prioritize key process steps from the start — to avoid delays and allow for fast production of high-quality products. I give some more recommendations here: https://lnkd.in/dMR44d6j

It was great to have the opportunity to interview Sam Clark, MD PhD, Founder and CEO of Terran Biosciences, to learn more about how his company is working to transform the lives of patients living with neurological and psychiatric illnesses. Terran has many exciting programs and technologies that they are researching, and it was great to hear Sam speak extensively on what Terran is working on. Spoiler alert for one of my favorite sections of the interview: Many drug development companies have been working on agonizing the 5-HT2A receptor in a manner that can potentially retain the therapeutic benefits of psychedelics, but without the associated hallucinogenic effects. Terran has taken a unique approach to non-hallucinogenic psychedelic drug development, by combining psychedelics with highly selective serotonin 2a antagonists. (Terran also has a large library of pre-clinical non-hallucinogenic neuroplastogens) Psychedelics hit many different receptor targets and it is known that the 2A receptor is the one responsible for the trip. By letting psychedelics hit all other receptors except for the 2A receptor, Terran believes they have the chance of having a therapeutic that can reach more people than classic psychedelics, and that may have potential in treating neurodegenerative diseases as well as depression and anxiety disorders. As Sam likes to say, “scientists have already cured all diseases known to mouse-kind”. Terran collaborated with a team at Yale and conducted an fMRI study looking at the drug combination in humans. The results, which Sam shares in this interview, look extremely promising! A lot was covered in this one. I hope everyone enjoys this interview as much as I did, and as always, learns something new.

Cell Expansion Market Worth to reach $26.7 billion by 2029 ???????????????? ?????? ???????????????? ???? https://lnkd.in/d-vV-5JB The global cell expansion market in terms of revenue was estimated to be worth $14.3 billion in 2024 and is poised to reach $26.7 billion by 2029, growing at a CAGR of 13.3% from 2024 to 2029. ?????? ?????????????????? ???????????????? ???? ???????? ???????????? ?????????????? ?Thermo Fisher Scientific, Inc. (US),?Danaher Corporation (US),?Merck KGaA (Germany),?Sartorius AG (Germany),?Corning Incorporated (US),?Lonza (Switzerland),?Terumo Corporation (Japan),?Eppendorf SE (Germany),?FUJIFILM Corporation (Japan),?Bio-Techne (US) ?????????? ?????????????????? ???????? ?????? ?????????????????? ???? ???????? ???????????? ????????????????: Scinus Cell Expansion B.V. Cellex - Cell Expansion Devices srl Nkarta, Inc. Pluri Deverra Therapeutics PL BioScience GmbH HemoGenix, Inc trenzyme GmbH Plasticell Limited CEIDOS Onkologic Inc. Oxford MEStar Ltd Cytocare Technologies Private Limited Cytion AcroCyte Therapeutics ATGen Canada/NKMax Canada Tantti Laboratory Inc. Cytomatrix Pty Ltd Zyxell Inc. Juncell Therapeutics ViBeams Symbiontt BioBro

AI Proteins announces collaboration with Bristol Myers Squibb - BMS to discover and develop novel miniprotein-based therapeutics valued up to $400M. ??Under this collaboration, AI Proteins will leverage its AI-driven platform to design and optimize miniproteins against targets of interest to #BMS ??https://lnkd.in/eEPBEwVH #GenAI #LLMs #GenerativeAI

AAVs are widely adopted but still pose challenges - as discussed in a new article by Angelo DePalma, Ph.D. in Biocompare. The article covers current challenges for rAAV-based therapeutics development, and the innovative solutions that are being developed to overcome them. Refeyn's Gabriella Kiss, Ph.D. explains in detail how #MassPhotometry supports efficient, scalable AAV manufacturing by enabling frequent testing and continuous process monitoring. Read the article here! https://lnkd.in/eq8UnG8v

Cell Expansion Market Worth to reach $26.7 billion by 2029 ???????????????? ?????? ???????????????? ???? https://lnkd.in/dtuaFF6g The global cell expansion market in terms of revenue was estimated to be worth $14.3 billion in 2024 and is poised to reach $26.7 billion by 2029, growing at a CAGR of 13.3% from 2024 to 2029. ?????? ?????????????????? ???????????????? ???? ???????? ???????????? ?????????????? ?Thermo Fisher Scientific, Inc. (US),?Danaher Corporation (US),?Merck KGaA (Germany),?Sartorius AG (Germany),?Corning Incorporated (US),?Lonza (Switzerland),?Terumo Corporation (Japan),?Eppendorf SE (Germany),?FUJIFILM Corporation (Japan),?Bio-Techne (US) ?????????? ?????????????????? ???????? ?????? ?????????????????? ???? ???????? ???????????? ????????????????: Scinus Cell Expansion B.V. Cellex - Cell Expansion Devices srl Nkarta, Inc. Pluri Deverra Therapeutics PL BioScience GmbH HemoGenix, Inc trenzyme GmbH Plasticell Limited CEIDOS Onkologic Inc. Oxford MEStar Ltd Cytocare Technologies Private Limited Cytion AcroCyte Therapeutics ATGen Canada/NKMax Canada Tantti Laboratory Inc. Cytomatrix Pty Ltd Zyxell Inc. Juncell Therapeutics ViBeams Symbiontt BioBro

?? IN CASE YOU MISSED IT | Rakovina Therapeutics Executive Chairman Jeffrey Bacha discusses #RKV's novel low-cost #drugdevelopment and partnering strategy targeting DNA-damage response inhibitors. Watch the interview here ? https://lnkd.in/giWETwBM #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics #AI

If you missed our recent webinar with Radius Research, you can watch it here.

CellarisBio's MICRO-TAG cell target engagement platform revolutionizes precision therapeutic discovery by offering a sophisticated and effective solution. This cutting-edge technology enhances the accuracy and efficiency of targeting challenging targets, facilitating the development of advanced therapeutics. #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #BiotechInnovation

City Therapeutics announces partnership with B+L to develop a novel RNAi-based treatment for GA. Read more: https://ow.ly/cq8i50ULrrH #RetinalPhysician #RPnews #GeographicAtrophy #GA #Conexiant